自体骨关节炎关节驻留干细胞与祖细胞用于软骨细胞治疗:浓度与生物学性能的定量比较
本研究对10例全膝关节置换患者的软骨(Outerbridge 1-3级)、骨髓浓缩液、髌下脂肪垫、滑膜和骨膜进行供体匹配的定量比较,分析细胞浓度、结缔组织祖细胞(CTP)患病率及基于体外增殖、集落密度和分化潜能的生物学性能。结论认为软骨(G1-2-3)基于CTP患病率和GAG-ECM表达是软骨修复的首选组织来源,其次为滑膜、IPFP、BMC和骨膜,但各组织内CTP生物学性能高度异质。
要点
- 软骨(G1-2-3级)的CTP患病率和GAG-ECM表达最高,为软骨修复首选来源。
- 滑膜和IPFP的CTP增殖能力最高,且存在与软骨性能相似的CTP亚群。
- 各组织来源内CTP生物学性能高度异质,提示可基于性能进行克隆筛选。
核心结论
- 不同组织来源在细胞浓度、CTP患病率和生物学属性上存在差异,软骨(G1-2-3)基于CTP患病率和GAG-ECM是软骨修复的首选组织来源,其次为滑膜、IPFP、BMC和骨膜。
研究设计与样本
- 描述性实验室研究,从10例接受全膝关节置换术的患者获取组织,平均年龄59岁,女性6例。
- 采用自动定量集落形成单位分析比较各组织来源的细胞浓度、CTP患病率和CTP生物学性能。
主要发现
- 细胞浓度在3级软骨(P = .002)和BMC(P = .001)中最高。
- 中位CTP患病率在IPFP(P = .001)、滑膜(P = .003)和G1-2软骨(P = .02)中最高。
- 滑膜来源CTP的增殖能力最高(P < .001)。
- 中位集落密度(P < .001)和中位GAG-ECM(P < .001)在G1-2-3软骨中最高。
- 每位患者内,所有组织来源的CTP在生物学性能(每集落细胞数、密度和GAG-ECM)上高度异质。
临床怎么用
- 软骨修复策略中可优先考虑软骨(G1-2-3)作为细胞来源,滑膜和IPFP可作为替代来源。
- 基于性能的克隆筛选和扩增优选CTP及其子代,可能获得具有预测未来的改进细胞群。
- 优化细胞来源可能需要将具有优选属性的CTP与较差属性的CTP分离。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cell-based therapy for cartilage repair is a promising approach and is becoming an established technique. Yet, there is no consensus on the optimal cell source. PURPOSE: To provide a donor-matched quantitative comparison of the connective tissue progenitors (CTPs) derived from cartilage (Outerbridge grade 1-3 [G1-2-3]), bone marrow aspirate concentrate (BMC), infrapatellar fat pad (IPFP), synovium, and periosteum with respect to (1) cell concentration ([Cell], cells/mL), (2) CTP prevalence (PCTP, colonies per million cells), and (3) biological performance based on in vitro proliferation potential (cells per colony) colony density, and differentiation potential (expression of negatively charged extracellular matrix: glycosaminoglycan-rich extra cellular matrix [GAG-ECM]). STUDY DESIGN: Descriptive laboratory study. METHODS: Tissues were obtained from 10 patients undergoing total knee arthroplasty (mean age, 59 years; women, n = 6). Automated quantitative colony-forming unit analysis was used to compare [Cell], PCTP, and CTP biological performance across tissue sources. RESULTS: [Cell] was highest in grade 3 cartilage (P = .002) and BMC (P = .001). Median PCTP was highest in IPFP (P = .001), synovium (P = .003), and G1-2 cartilage (P = .02). Proliferation was highest in synovium-derived CTPs (P < .001). Median colony density was highest in G1-2-3 (P < .001). Median GAG-ECM was highest in G1-2-3 (P < .001). Within each patient, CTPs derived from all tissues were highly heterogeneous in biological performance as determined by cells per colony, density, and GAG-ECM. CONCLUSION: Tissue sources differ in [Cell], PCTP, and biological attributes. The data presented in this study suggest that cartilage (G1-2-3) is the preferred tissue source for cartilage repair based on PCTP and GAG-ECM, followed by synovium, IPFP, BMC, and periosteum. However, due to the heterogeneous mixture of CTPs within each tissue source, there exists a subset of CTPs with biological performance similar to G1-2-3 cartilage, particularly in synovium and IPFP. Performance-based clonal selection and expansion of preferred CTPs and their progeny will potentially lead to improved cell population with predictive future. CLINICAL RELEVANCE: Optimal tissue regeneration strategies will require informed decisions regarding which of the available tissue sources to use. Optimizing cell sourcing in any tissue may require separation of CTPs with preferred attributes from those with less desirable attributes. The heterogeneity manifest in the early stage of colony formation represents an opportunity for performance-based clone selection for clinical cell processing and manufacturing.
引用
- Mantripragada VP, Bova WA, Piuzzi NS, et al. Native-Osteoarthritic Joint Resident Stem and Progenitor Cells for Cartilage Cell-Based Therapies: A Quantitative Comparison With Respect to Concentration and Biological Performance. Am J Sports Med. 2019. PMID: 31671273. doi:10.1177/0363546519880905
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。